|
EORTC AISBL / IVZW |
Open studies are marked with a purple background, closed studies have a grey background, studies to be opened have a white background
| 16006 | Open label phase II of MEN-10755 administered every 3 weeks in patients with progressive hormone refractory prostate cancer |